

January 2014

Dear Colleague,

On behalf of Pan Stanford Publishing, we invite you to contribute a book chapter for a review volume titled ***Immune Effects of Biopharmaceuticals and Nanomedicines*** that we are currently editing. The deadline for the book chapter in final format is **July 1, 2014 or earlier**. This review volume will be volume 2 in the *Pan Stanford Series on Nanomedicine*. The 75-chapter Volume 1 of this series titled *Handbook of Clinical Nanomedicine - From Bench to Bedside* is currently in press and will be published this year. Your chapter will undergo peer-review and the 30+-chapter book will be published in late 2014 (The book will be advertised on Amazon, Barnes & Noble and various other outlets). In addition, the book will be copyedited and proofread by the publisher. Kindly note that this invitation does not automatically imply inclusion in the book; final approval will be granted by the editors and primarily based on the peer reviews.

The book aims to provide a broad survey of various topics pertaining to the immune effects of biopharmaceuticals and nanomedicines, both beneficial and adverse. Thus, chapters will be devoted to immune stimulatory and suppressive effects of monoclonals, peptides and other biopharmaceuticals, drug carrier liposomes, micelles, polymers, polymeric vesicles, dendrimers, carbon nanotubes and many other particulate pharmaceuticals and other nanomedicines with and without surface targeting ligand. The state-of-art in nanoparticle-formulated therapeutic and preventive vaccines will also be presented, as well as the molecular mechanism underlying their immunogenicity. The latter phenomenon, on the other hand, will also be addressed as an adverse effect of monoclonal antibody-based biopharmaceuticals and nanomedicines. Yet another adverse immune effect of monoclonals and nanomedicines, complement activation-related pseudoallergy (CARPA), will be discussed in unprecedented detail in terms of occurrence, prediction, prevention and mechanism. With contributions from international experts, the editors have an extensive track record to produce a book that will provide a unified perspective to these varied topics. Each chapter will have an abstract, 10-20 key words, a "Conclusion and Future Prospects" section and an extensive list of references. The book will be essential reading for the novice and expert alike in diverse fields such as medicine, law, biotechnology, pharmaceutical sciences, engineering, policy, future studies, ethics and toxicology. The book will serve as a valuable reference resource for industry, academia and government. We expect the final book to have 30+ review chapters with extensive tables and figures. If needed, the publisher will assist you in obtaining copyright permission. Depending on the scope that you wish to present, the chapter should be around **10-25 double-spaced pages maximum**. Please include any illustrations, figures, tables and graphs within the body of the chapter. Whenever appropriate, the hardbound book will feature figures in color.

There will be no financial obligations incurred by you. In appreciation of your efforts, a complimentary copy of the volume will be given to each corresponding author. To ensure that we achieve the full complement of chapters and embark upon the publication of this book in a timely manner, please let one of the editors listed below know via email that you accept this invitation. If you agree to contribute, we would be grateful if you can submit a tentative title of your chapter along with your full affiliation/contact information as soon as possible so that they can be included in the "Table of Contents" that we are currently developing. We will provide you with further details at that time, including format details and a sample chapter that you can use as a template. Feel free to contact us should you have any questions or would like to discuss potential topics for your chapter. Thank you for your attention and we look forward to your reply soon.

Sincerely,

János Szebeni, MD, PhD, DSc,
Director, Nanomedicine Research and Education Center, School of Medicine, Semmelweis University, Budapest, 1089 Nagyvárud tér 4, Hungary
Professor of (Immune) Biology, Faculty of Health Sciences, Miskolc University in Miskolc, Hungary
Email: jszebeni2@gmail.com
Tel: 36-30-415-0007

Raj Bawa, MS, PhD
Patent Agent, Bawa Biotech LLC, 21005 Starflower Way, Ashburn, Virginia 20147, USA
Adjunct Professor, Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, New York, USA
Scientific Advisor, Teva Pharmaceutical Industries Ltd., Israel
Email: bawa@bawabiotech.com
Tel: 703-582-1745